Exudation in Patients with Neovascular Age-Related Macular Degeneration Treated with the Port Delivery System or Monthly Injections

Vascular endothelial growth factor-A (VEGF-A) is a critical stimulus for neovascularization (NV) and excessive vascular leakage resulting in exudation and reduced vision in patients with neovascular age-related macular degeneration (nAMD). 1 Monthly injections of ranibizumab or injections of aflibercept every other month control exudation in most patients and provide substantial improvement in vision.2-4 Observational studies have demonstrated that in clinical practice injection frequency of anti-VEGF agents in patients with nAMD is substantially lower than that in clinical trials and visual outcomes are much worse.

Source: American Journal of Ophthalmology - July 13, 2023 Category: Opthalmology Authors: Anam Akhlaq, David Williams, W. Lloyd Clark, Hannah Khan, Arshad M. Khanani, Lisa Walden, Carl Awh, J. Taylor Graff, Jordan M. Graff, Taku Wakabayashi, Carl Regillo, Katie F. Maass, Natalia Callaway, Shamika Gune, Peter A. Campochiaro Tags: Original Articles Source Type: research